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SUMMARY
As an important regulator of macrophage cholesterol
efflux and HDL biogenesis, miR-33 is a promising
target for treatment of atherosclerosis, and numerous
studies demonstrate that inhibition of miR-33 in-
creases HDL levels and reduces plaque burden. How-
ever, important questions remain about how miR-33
impacts atherogenesis, including whether this pro-
tection is primarily due to direct effects on plaque
macrophages or regulation of lipid metabolism in
the liver. We demonstrate that miR-33 deficiency in
Ldlr/ mice promotes obesity, insulin resistance,
and hyperlipidemia but does not impact plaquedevel-
opment. We further assess how loss of miR-33 or
addition of miR-33b in macrophages and other
hematopoietic cells impact atherogenesis. Macro-
phage-specific loss of miR-33 decreases lipid accu-
mulation and inflammation under hyperlipidemic con-
ditions, leading to reduced plaque burden. Therefore,
the pro-atherogenic effects observed in miR-33-defi-
cient mice are likely counterbalanced by protective
effects in macrophages, which may be the primary
mechanism through which anti-miR-33 therapies
reduce atherosclerosis.
INTRODUCTION
MicroRNAs (miRNAs) have been demonstrated to play a key role
in the control of mRNA translation and degradation, constituting
an entirely new level of posttranscriptional regulation that
is involved in nearly all biological processes (Ambros, 2004;
Bartel, 2009; Ferna´ndez-Hernando et al., 2011, 2013). Targeting
miRNAs is a promising therapeutic approach, as they are dysre-
gulated during and involved in the development ofmany different
disease states (Barwari et al., 2016; Poller et al., 2017). Recent
work has elucidated the role of miRNAs in the development of
numerous metabolic conditions, including obesity, type II dia-
betes, and cardiovascular disease, which are responsible for
the majority of chronic illnesses and deaths in the United States
and other developed countries. Many factors, including insulin
signaling, inflammation, autophagy, mitochondrial function,
and lipid metabolism, are involved in the development of these
cardiometabolic diseases, and previous work suggests a role
for miR-33 in regulating all of these critical processes (Allen
et al., 2012; Da´valos et al., 2011; Goedeke et al., 2013; Karuna-
karan et al., 2015; Marquart et al., 2010; Ouimet et al., 2015,
2017; Rayner et al., 2010).
ThemiR-33miRNA family, which consists of miR-33a andmiR-
33b, is one of the most well-characterized examples of miRNA-
mediated regulation of lipid metabolism (Marquart et al., 2010;
Najafi-Shoushtari et al., 2010; Rayner et al., 2010). miR-33a and
miR-33b are intronic miRNAs encoded within the SREBP-2 and
SREBP-1 genes, respectively (Marquart et al., 2010; Najafi-
Shoushtari et al., 2010; Rayner et al., 2010). Sterol response
element binding protein (SREBP)-1 and SREBP-2 are two of the
most important transcription factors involved in the regulation of
fatty acid and cholesterol metabolism, respectively (Horton
et al., 2002). As such, the discovery of miRNAs within intronic re-
gions of the genes that encode these key transcription factors
directed multiple groups to investigate whether miR-33a and
miR-33b may also be involved in the regulation of lipid meta-
bolism. This work led to the demonstration that miR-33a and
miR-33b are co-transcribed along with SREBP-2 and SREBP-1
and work in concert with their host genes to help maintain proper
lipid levels within the cell (Da´valos et al., 2011; Marquart et al.,
2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010). While
the SREBP transcription factors prevent deleterious reductions
in cellular lipid levels by promoting lipid synthesis and uptake,
miR-33a andmiR-33b help prevent further loss of lipids by target-
ing genes involved in cholesterol trafficking and efflux (Niemann
Pick C [NPC1], ATP-Binding Casette A1 [ABCA1], and ATP-Bind-
ing Casette G1 [ABCG1]) (Marquart et al., 2010; Najafi-Shoushtari
et al., 2010; Rayner et al., 2010) and fatty acid b-oxidation
(carnitine palmitoyltransferase 1A [CPT1A], carnitine O-octanoyl-
transferase [CROT], andhydroxyacyl-coenzymeA [CoA]dehydro-
genase/3-ketoacy-CoA thiolase/enoyl-CoA hydratase b subunit
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[HADHB]) (Da´valos et al., 2011; Gerin et al., 2010). In addition to
regulating cellular cholesterol efflux, ABCA1 also controls the
biogenesis of high-density lipoproteins (HDLs) and a number of
groups have demonstrated that in vivo antagonism or genetic
deletion of miR-33 enhances hepatic ABCA1 expression and in-
creases circulating HDL-cholesterol (HDL-C) (Marquart et al.,
2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010). Further
work has demonstrated an additional mechanism by which the
miR-33 family prevents lipid depletion in the liver by targeting
genes regulating bile acid synthesis and secretion (ATP-binding
cassette subfamily B member 11 [ABCB11], amino phospholipid
transporter class I type 8B member 1 [ATP8B1], and cytochrome
P450 family 7, subfamily A, polypeptide 1 [CYP7A1]) (Allen et al.,
2012; Li et al., 2013). Together, these studies established that
miR-33 is an important regulator of many facets of lipid meta-
bolism, including several stepsof the reversecholesterol transport
(RCT)pathway, theprocess bywhich cholesterol is returned to the
liver for conversion into bile acids and removal via the feces (Lewis
and Rader, 2005; Rader and Hovingh, 2014).
RCT is the only mechanism by which arterial macrophages
(Mqs) can remove excess cholesterol, thereby reducing the for-
mation of atherosclerotic plaques by limiting the accumulation
of lipid-laden Mqs within the arterial wall (Rosenson et al.,
2012). As such, miR-33 has been demonstrated to be an impor-
tant factor in controlling the development of atherosclerosis,
and a great deal of work has been done exploring the possible
therapeutic value of inhibiting miR-33 during atherogenesis.
Numerous reports have demonstrated that antagonism of
miR-33 in mouse models of atherosclerosis can reduce plaque
burden by either impeding the progression or promoting the
regression of atherosclerotic plaques (Rayner et al., 2011b; Rotl-
lan et al., 2013). However, other similar studies did not observe
any beneficial effects of anti-miR-33 therapy on atherogenesis
(Marquart et al., 2013). Additionally, some studies of long-term
anti-miR-33 treatment have reported deleterious effects,
including increased circulating levels of triglycerides (TAGs)
and the development of hepatic steatosis (Allen et al., 2014;
Goedeke et al., 2014). Most of the beneficial effects of miR-33
on atherosclerosis have been attributed to its ability to increase
circulating levels of HDL-C and/or promote Mq cholesterol efflux
(Rayner et al., 2010, 2011b), although additional functions of
miR-33, including regulation of mitochondrial function, auto-
phagy, andMq activation status, may also contribute to these ef-
fects (Karunakaran et al., 2015; Ouimet et al., 2015, 2017).
Importantly, studies performed in monkeys have demonstrated
that antagonism of miR-33 can also increase circulating levels
of HDL-C in non-human primates (Rayner et al., 2011a; Rottiers
et al., 2013). These findings are especially relevant, as the in-
tronic region of the SREBP-1 gene encoding miR-33b is disrup-
ted in rodents and other small mammals. Because of the inability
to study miR-33b using most conventional animal models, many
questions still remain about its specific role in regulation of
atherosclerosis and other metabolic disease.
In order to properly assess the possible therapeutic value of
anti-miR-33 therapies, it will be necessary to determine whether
increased HDL biogenesis or improved cholesterol efflux from
plaque Mqs is primarily responsible for mediating the beneficial
effects that have been reported. This question is especially rele-
vant, as recent clinical trials have demonstrated that other thera-
peutic approaches, though effective at raising circulating HDL-C
levels, did not appear to have any impact on clinical outcomes in
patients with cardiovascular disease. To begin to address this
question, Horie and colleagues created mice deficient in
miR-33 (Horie et al., 2010). By crossing these animals into the
Apoe/ mouse model of atherosclerosis, they were able to
demonstrate that whole-body loss of miR-33 reduces athero-
sclerotic plaque size and lipid content (Horie et al., 2012). Addi-
tionally, bone marrow transplant from miR-33-deficient animals
into Apoe/ mice, to selectively remove miR-33 from Mqs and
other hematopoietic cells, was found to reduce lipid content in
atherosclerotic plaques but did not have a significant impact on
plaque size (Horie et al., 2012). This study suggests that both
increased circulating HDL-C levels and improved efflux of
cholesterol from arterial Mqs may contribute to the ability of
anti-miR-33 therapies to reduced atherosclerotic plaque burden.
While this work provides some insight into the potential impact
of whole-body- versus Mq-specific antagonism of miR-33, the
potential relevance of these findings is limited by the nature of
the atherosclerotic mouse model that was used. Because both
HDL-C levels and RCT are dramatically reduced in Apoe/
mice, the elevated HDL-C levels seen in mice lacking miR-33
may be substantially more impactful. At the same time, work
done using this model may underestimate the impact of
miR-33 on regulating Mq cholesterol efflux, as ABCA1 and
ABCG1, two of the most well established targets of miR-33,
are primarily responsible for transport of cholesterol onto circu-
lating HDL particles. Additionally, a later report by this same
group has demonstrated that loss of miR-33 results in a predis-
position to the development of obesity and insulin resistance
(Horie et al., 2013), but the impact of these effects on atheroscle-
rosis is unclear, as these phenotypes were not reported in their
earlier work in the Apoe/ background.
In this work, we attempt to address many of the outstanding
questions regarding how miR-33 regulates atherosclerotic pla-
que development. To do this, we have generated a novel
miR-33 knockout mouse model (miR-33/) and utilized these
mice to assess how loss of miR-33 impacts atherosclerosis in
the Ldlr/ mouse model of atherosclerosis, in which HDL-C
levels and RCT capacity are similar to those in wild-type (WT)
mice. Using this model, we are able to demonstrate that
miR-33 deficiency results in elevated expression of ABCA1 in
both the liver and Mqs and enhances the capacity of Mqs to
efflux cholesterol in vivo, leading to a dramatic reduction in the
accumulation of cholesterol esters in miR-33/ Mqs under hy-
perlipidemic conditions. Consistent with this, we observe that
selective loss of miR-33 in Mqs and other hematopoietic cells re-
sults in a substantial reduction in both atherosclerotic plaque
size and lipid content. We further demonstrate that both the
number of apoptotic cells and the size of the necrotic cores
are reduced in plaques from mice transplanted with miR-33/
bone marrow, indicative of increased plaque stability. Alterna-
tively, whole-body loss of miR-33 in Ldlr/ mice was found to
result in increased body weight (BW), impaired insulin sensitivity,
and a pro-atherogenic lipid profile. These effects appear to have
offset the beneficial effects of miR-33 within the atherosclerotic
plaques, as no difference was found in the plaque size or lipid
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accumulation of Ldlr/miR-33/ double-knockout (DKO)mice,
compared to Ldlr/ controls. We further assess howmiR-33b in
Mqs impacts atherosclerotic plaque formation using a newly
generated mouse model in which the mouse Srebp-1 gene has
been replaced with the human form, including the intronic region
encoding miR-33b (miR-33bKI). Finally, we have performed in-
depth RNA sequencing under both normal and hyperlipidemic
(Ldlr/) conditions to provide a more complete view of the
impact that ablation of miR-33 has on Mq gene expression.
Together, these findings help clarify the role of miR-33 in the
development of atherosclerosis and highlight both the beneficial
effects of removingmiR-33 in arterial Mqs to promote cholesterol
efflux from within atherosclerotic plaques and the deleterious
effects that loss of miR-33 in other tissues may have on athero-
genesis and other metabolic conditions.
RESULTS
Generation of miR-33 Knockout Mice
To address some of the primary unresolved questions surround-
ing how miR-33 regulates atherosclerosis, we utilized CRISPR/
Cas9 technology to excise the intronic region of the Srebp-2
gene encoding miR-33, thus generating a new miR-33 knockout
mouse model (miR-33/). This excision of roughly 200 bp can
be readily confirmed by PCR analysis and has been used to
detect effective excision of the miR-33 sequence in all tissues
examined (Figure 1A). Consistent with previous studies, western
blot analysis of the liver of miR-33/ mice reveals increased
expression of miR-33 target genes ABCA1 and HADHb,
compared to control animals, while other miR-33 targets,
including CROT, were unaffected (Figure 1B). Consistent with
the observed increase in ABCA1 expression, plasma HDL-C
levels were found to be elevated inmiR-33/mice as visualized
by fast protein liquid chromatography (FPLC) fractionation
(Figure 1C) and confirmed by quantification of circulating
HDL-C levels (Figure 1D).
Ldlr/miR-33/Mice Have Increased BW and Impaired
Insulin Sensitivity
Following initial characterization,miR-33/mice were bred into
the low-density lipoprotein receptor (LDLR)-deficient model of
mouse atherosclerosis (Ldlr/) to generate Ldlr/miR-33/
(DKO) mice. Similar to earlier work on miR-33-deficient mice
fed a high-fat diet (HFD), our DKO mice had significantly higher
BW compared to Ldlr/ controls, which was exacerbated by
feeding a pro-atherogenic western diet (WD; 1.25% cholesterol)
(Figure 1E). Additionally, following 10 weeks ofWD feeding, DKO
animals showed reduced responsiveness to insulin during an
insulin tolerance test (Figure 1F), indicating impaired insulin
sensitivity. However, this was not sufficient to disrupt regulation
of glucose homeostasis, as neither glucose tolerance tests
(Figure 1G) nor measurement of fed and fasted blood glucose
levels (Figure 1H) revealed any difference between Ldlr/ and
DKOmice at this time. DKOmice also had higher levels of circu-
lating insulin, suggesting that increased insulin production was
able to compensate for the impaired insulin sensitivity (Figure 1I).
FPLC fractionation of plasma from Ldlr/ and DKO mice
following 12 weeks of WD feeding showed that DKO mice had
a substantial increase in the amount of cholesterol (Figure 1J)
and triglycerides (TAGs) (Figure 1K) in fractions containing
very-low-density lipoprotein (VLDL) and low-density lipoprotein
(LDL) particles. Furthermore, western blot analysis on FPLC frac-
tions from DKOmice further demonstrates increased expression
of the apolipoproteins associatedwith these particles (Figure 1L).
Finally, DKO mice also had elevated total levels of TAGs and
cholesterol compared to Ldlr/ controls, while HDL-C levels
were not altered (Figures 1M–1O). The similar HDL-C levels
observed between Ldlr/ and DKO mice may be due to the
repression of SREBP-2 and miR-33 under hyperlipidemic condi-
tions (Rotllan et al., 2013).
Loss of miR-33 in Ldlr/ Mice Does Not Impact Plaque
Size or Morphology
Despite the increased BW, insulin resistance (IR), and pro-
atherogenic lipid profile observed in DKOmice, histological anal-
ysis of progressive sections of the aortic root did not reveal any
major differences between DKO mice and Ldlr/ controls. No
significant changes were observed in total plaque area or lipid
accumulation, as indicated by oil red O (ORO) staining for neutral
lipids (Figure 2A). Similarly, en face analysis of lipid accumulation
in the aorta did not show any differences between DKO and
Ldlr/mice (Figure 2B), and measurements of circulating blood
leukocytes by fluorescence-activated cell sorting (FACS) and
HEMAVET did not reveal any significant differences between
groups (Figures S1A and S1B). These findings are contrary to
what has been previously observed in most studies in animals
treated with anti-miR-33 therapies as well as miR-33-deficient
Apoe/ mice. While further work is needed to fully understand
the mechanisms underlying the detrimental whole-body
changes observed in DKO mice, these findings could suggest
that the beneficial effects of removing miR-33 within arterial
Mqs may offset these negative effects.
Hematopoietic-Specific Loss of miR-33 Impedes the
Development of Atherosclerotic Plaques
To directly address the question of how loss of miR-33 within the
Mqs making up atherosclerotic plaques impacts atherogenesis,
we performed bone marrow transplants (BMTs) into lethally irra-
diated Ldlr/ mice using bone marrow (BM) from either WT or
miR-33/ mice. Unlike comparisons between Ldlr/ and
DKO mice, animals transplanted with BM from miR-33/ mice
did not have any differences in plasma lipids or lipoprotein profile
(Figures S1C–S1F) and also did not show significant changes in
levels of circulating leukocytes (Figures S2A and S2B). However,
following 12 weeks of WD feeding, atherosclerotic plaque
burden was substantially reduced in mice transplanted with
BM from miR-33/ animals. Histological analysis of the aortic
root revealed a significant reduction in both total plaque area
and lipid accumulation (Figure 3A), and further analysis of en
face preps of the aorta also demonstrated a significant decrease
in lipid accumulation (Figure 3B). More detailed analysis of these
plaques showed that the size of the necrotic core was also
decreased in mice transplanted with miR-33/ BM (Figure 3C).
The percentage of plaque area that stained positive for the Mq
marker CD68 was similar to that of control animals, indicating
that the proportion of the plaque made up of macrophages
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was not impacted by loss of miR-33. Alternatively, CD68/TUNEL
co-staining was decreased in plaques from animals that
received miR-33/ BM, indicating that Mq apoptosis may
contribute to the elevated formation of necrotic cores in WT
animals (Figure 3D). Furthermore, by digesting the aortas of
WD-fed mice and performing FACS analysis, we were able to
show a significant decrease in the number of both total and acti-
vated (Ly-6Chigh) Mqs in plaques from mice transplanted with
miR-33/BM (Figure 3E). Together, these findings demonstrate
that, while hematopoietic loss of miR-33 does not alter the pro-
portion of the plaque that ismade up ofmacrophages, there is an
overall decrease in the number of macrophages within the arte-
rial wall corresponding to the overall decrease in plaque size.
Generation of miR-33b Knockin Mice
While these findings highlight the important role of Mq miR-33
in the regulation of atherogenesis in mice, the situation is
more complicated in humans due to the presence of a second
Figure 1. Global Deletion of miR-33 in Ldlr/ Mice Results in Obesity, IR, and Dyslipidemia
(A) Strategy used to generate miR-33/ mice (upper panel). PCR analysis of tail DNA isolated from WT, miR-33+/, and miR-33/ mice (middle panel). PCR
analysis showing the deletion of miR-33 in the indicated tissues (bottom panel).
(B) Representative western blot analysis of ABCA1, CROT, and HADHB in liver samples isolated from WT and miR-33/ mice. Relative protein levels were
determined by band densitometry and are expressed in a.u. after correction for loading control actin (n = 3).
(C) Lipoprotein profile analysis from pooled plasma of WT and miR-33/ mice.
(D) Plasma HDL-C levels from WT and miR-33/ mice (n = 9).
(E) BW of Ldlr/ and Ldlr/miR-33/ (DKO) mice fed a western diet (WD) for 10 weeks (n = 9).
(F and G) Insulin tolerance test (ITT) (F) and glucose tolerance test (GTT) (G) in Ldlr/ and DKO mice fed a WD for 10 weeks (n = 6–7). Inset represents the area
under the curve (AUC).
(H) Plasma glucose levels in fed and fasted 2-month-old Ldlr/ and DKO mice (n = 7).
(I) Plasma insulin levels in fasted Ldlr/ and DKO mice fed a WD for 12 weeks.
(J and K) Cholesterol (J) and TAG content (K) of FPLC-fractionated lipoproteins from pooled plasma of Ldlr/ and DKO mice fed a WD for 12 weeks.
(L) Western blot analysis (representative of two blots) of plasma APOB and APOA1 in the FPLC-fractionated lipoproteins in panel. Lanes 1–13 correspond to the
following pooled fractions: 1 (28–30), 2 (31–33), 3 (34–36), 4 (37–39), 5 (40–42), 6 (43–45), 7 (46–48), 8 (49–51), 9 (52–54), 10 (55–57), 11 (58–60), 12 (61–63), and 13
(64–66).
(M–O) Plasma TAGs (M), total cholesterol (N), and HDL-C (O) in the plasma of Ldlr/ and DKO mice fed a WD for 12 weeks (n = 11–16).
All data represent mean ± SEM. *p < 0.05, comparing miR-33/ with WT mice or DKO with LDLR/ mice on the same diet.
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miR-33 isoform, miR-33b. To determine whether miR-33b may
also impact atherosclerosis, we generated a novel mouse model
in which the entire mouse Srebp-1 gene has been replaced with
the human sequence, including the region encoding miR-33b,
under the control of the mouse promoter (miR-33bKI). Insertion
of this construct can be confirmed by the presence of the neo
cassette, which was later excised, or with specific primers
demonstrating the presence of human Srebp-1 or the loss of
mouse Srebp-1 (Figure S3A). Furthermore, the introduction of
human SREBP-1 and miR-33b, and the loss of mouse Srebp-1
in homozygous miR-33bKI mice, was confirmed by qPCR anal-
ysis (Figures S3B, S3C, and S3E). Importantly, this analysis
also demonstrates that the expression of Srebp-2 and miR-33a
was not altered by the addition of miR-33b (Figures S3D and
S3F). Expression of miR-33bwas detected in a variety of tissues,
among which the liver showed the highest expression levels
(Figure S3G). This is consistent with what has previously been
shown for miR-33b in human tissues (Najafi-Shoushtari et al.,
2010). Human SREBP-1 also had high levels of expression in
the liver, although it was also highly expressed in other tissues,
including the white adipose tissue (WAT) and kidney, which
had relatively low levels of miR-33b expression (Figure S3H).
Reconstitution with BM from Cells Expressing miR-33b
Does Not Impact Atherosclerotic Plaque Formation
Similar toBMTexperimentswithmiR-33/mice, transplantation
of Ldlr/mice with BM frommiR-33bKI animals did not have any
impact on lipid profiles or circulating blood leukocytes (Figures
S4A–S4D). Unlike the loss of miR-33, however, introduction of
Figure 2. Germline Deficiency of miR-33
Does Not Influence the Progression of
Atherosclerosis
(A) Representative histological analysis of cross-
sections of the aortic sinus stained with H&E (upper
panels) or oil red O (ORO; bottom panels) of Ldlr/
and Ldlr/miR-33/ (DKO) mice fed a western
diet (WD) for 12 weeks. Right panels: the mean
lesion area and neutral lipid accumulation calcu-
lated from H&E and ORO aortic cross-sections,
respectively. Each dot represents the mean of the
quantification of R9 sections from an individual
animal (n = 10–11 animals per group).
(B) Representative en face ORO staining of 4 aortas
from Ldlr/ and DKOmice fed a WD for 12 weeks.
Quantification of the ORO-positive area is shown
in the right panel and represents the mean ± SEM
(n = 10).
All data represent mean ± SEM. *p < 0.05,
comparingDKOwith Ldlr/mice on the same diet.
NS, not significant.
Mqs expressing miR-33b also did not
have any impact on total plaque size or
lipid accumulation in either the aortic root
orwhole aorta (FigureS5A). These findings
are likely due to the low levels of expres-
sion of miR-33b within Mqs compared to
that of miR-33a. While miR-33b can be
readily detected in Mqs either from miR-
33bKImice or derived from human peripheral bloodmononuclear
cells (PBMCs), its expression in these cells is dramatically lower
than that of miR-33a (Figure S5B). Consistent with this, the
expression of miR-33 target genes was not changed in Mqs
from miR-33bKI mice either under basal conditions, following
stimulation with an LXR ligand (T0901317), or loading with acety-
lated LDL (Ac-LDL) (Figure S5C). Unfortunately, assessment of
how addition of miR-33b across the whole body impacts athero-
sclerosis was not possible, due to the sub-Mendelian birth rates,
poor survival, and reduced size ofmiR-33bKI mice.
Loss of miR-33 Improves Mq RCT In Vivo
Although the metabolic differences observed inmiR-33/mice
did not impede overall assessment of atherogenesis, the altered
BW, IR, and lipid levels of DKO mice preclude any direct exami-
nation of how changes in HDL biogenesis contribute to these
changes. As such, we next sought to better understand the
mechanisms underlying the beneficial effects observed in BMT
experiments with miR-33-deficient donors. Previous work has
demonstrated that inhibition of miR-33 enhances Mq cholesterol
efflux (Marquart et al., 2010; Najafi-Shoushtari et al., 2010; Ray-
ner et al., 2010). Consistent with this, we found that the expres-
sion of ABCA1 and ABCG1 is increased in Mqs isolated from
miR-33/ mice (Figure 4A). Next, we determined whether the
absence of miR-33 in Mqs enhances RCT. To this end, bone-
marrow-derived Mqs (BMDMs) from WT or miR-33/ mice
were differentiated in vitro, pre-loaded with [H3]-cholesterol,
and injected into the peritoneal cavity of WT mice (Figure 4B).
By quantifying the amount of [H3]-cholesterol incorporated into
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the blood and feces of these animals over 48 hr, we were able to
demonstrate that loss of miR-33 improves RCT fromMqs in vivo,
resulting in a significant increase in radioactivity counts in both
the plasmaand feces (Figure 4C). These results represent the first
demonstration that lossofmiR-33 inMqsacceleratesRCT invivo.
Mqs Lacking miR-33 Have Reduced Levels of
Cholesterol Esters and Phospholipids
To determine how this increased RCT capacity impacts the lipid
content of miR-33/ Mqs, we performed lipidomic analysis of
thioglycollate-elicited peritoneal Mqs from WT, miR-33/,
LDLR/, andDKOmice under normal (WT) or hypercholesterol-
emic (Ldlr/) conditions (Figure 4D). Consistent with our previ-
ous results, we observe a significant decrease in the accumula-
tion of cholesterol esters (CEs) in miR-33-deficient Mqs from
Ldlr/ mice (Figure 4E), including reductions in all CE subspe-
cies (Figure 4F). Interestingly, in a WT background, loss of
miR-33 was also found to significantly reduce the amount of
Mq phosphatidylethanolamines (PEs) and phosphatidylserines
(PSs) (Figures 4E and 4G). These lipid subspecies are important
Figure 3. Hematopoietic miR-33 Deficiency Attenuates Atherogenesis
(A) Left: representative histological analysis of cross-sections of the aortic sinus stained with H&E (upper panels) or oil red O (ORO; lower panels) of Ldlr/mice
transplanted withWT ormiR-33/ bonemarrow (BM) fed awestern diet (WD) for 12 weeks. Right: themean lesion area and neutral lipid accumulation calculated
from H&E or ORO aortic cross-sections, respectively. Each dot represents the mean of the quantification of R9 sections from an individual animal (n = 8–11
animals per group).
(B) Representative en face ORO staining of aortas from Ldlr/mice transplanted with WT and miR-33/ BM and fed a WD for 12 weeks. Quantification of the
ORO-positive area is shown in the right panel and represents the mean ± SEM (n = 10–11 per group).
(C) Representative images of aortic root cross-sections stained with H&E from Ldlr/ mice transplanted with WT or miR-33/ BM fed a WD for 12 weeks.
Images reveal how the necrotic core area was defined for quantification in each section. Dashed lines indicate the boundary of the developing necrotic core
(NC). Quantification is shown in the right panel. Each dot represents the mean of the quantification ofR9 sections from an individual animal (n = 10 animals per
group).
(D) Representative cross-section analysis of macrophage (Mq) content (CD68-positive cells; upper panels) and apoptotic cells (TUNEL-positive cells; bottom
panels) of the aortic root from Ldlr/mice transplanted with WT ormiR-33/ BM and fed a WD for 12 weeks. Quantifications are the graphs on the right. Each
dot represents the mean of the quantification ofR9 sections from an individual animal (n = 9–11 animals per group).
(E) Flow cytometry analysis of aortic Mqs and monocytes from Ldlr/ mice transplanted with WT or miR-33/ BM and fed a WD for 12 weeks. Left: repre-
sentative dot plots showing gating schemes. Right: quantification of total number of Mqs or Ly-6Chigh monocytes per aorta (n = 6).
All data represent mean ± SEM. *p < 0.05, comparing Ldlr/mice transplanted withmiR-33/ BM to Ldlr/mice transplanted with WT BM on the same diet.
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components of cellular membranes and are involved in a number
of important cellular functions, including apoptosis, migration,
and phagocytosis (Greenberg et al., 2006; Marin˜o and Kroemer,
2013; Shiratsuchi et al., 1998).
Mqs Deficient in miR-33 Do Not Show Differences in
In Vitro Polarization or Apoptosis but Do Have Increased
Efferocytosis Capacity
To further determine what effects of miR-33 deficiency in Mqs
may contribute to the observed differences in plaque formation,
we performed a series of experiments to assess Mq functions
related to atherogenesis. Previous reports have suggested that
miR-33 can directly regulate Mq activation status and inflamma-
tory response (Ouimet et al., 2015; Rayner et al., 2011b), and our
own data show that the number of Ly-6Chi-activated Mqs (M1-
like) is reduced in plaques from mice reconstituted with miR-
33/ BM. However, induction of Mq polarization in vitro did
not reveal any significant differences between WT and miR-
33/ Mqs (Figures S6A–S6G). Treatment with lipopolysaccha-
ride (LPS)/interferon (IFN)g stimulates the BMDM toward a clas-
sical (M1-like) activation status and induction of a number of
inflammatory genes. While the induction of interleukin (IL)-6
and IL-1b is somewhat diminished in Mqs deficient in miR-33,
these changes do not reach statistical significance (Figures
S6A and S6B). Moreover, loss of miR-33 does not have any
impact on the induction of other markers of classically activated
Figure 4. Absence of miR-33 in Macrophages Increases ABCA1 Expression, Enhances RCT, and Attenuates Lipid Accumulation In Vivo
(A) Representative western blot analysis of ABCA1 and ABCG1 expression in peritoneal macrophages (Mqs) isolated fromWT andmiR-33/mice untreated and
treated with T0901317. HSP90 is used as a loading control.
(B) Schematic representation of the RCT experiment. WT and miR-33/ bone-marrow-derived Mqs (BMDM) are loaded with [3H]-cholesterol and injected into
WT mice. Exit of [3H]-cholesterol from Mqs is measured in the plasma and feces 48 hr after injection.
(C) [3H]-cholesterol in plasma (left panel) and in feces (right panel) from WT mice injected subcutaneously with [3H]-cholesterol-labeled BMDM from WT or
miR-33/ mice (n = 18).
(D) Schematic representation of the lipidomic and genomic analyses of Mq foam cells isolated in vivo from Ldlr/ and Ldlr/miR-33/ (DKO) mice fed a chow
diet (CD) or western diet (WD) for 12 weeks.
(E–G) Lipidomic analysis of WT,miR-33/, Ldlr/, and DKO Mqs. (E) Levels of ceramides, phosphatidylcholine (PC), lysophosphatidylcoline (LPC), cholesterol
esters (CE), phosphatidylethanolamine (PE), and phosphatidylserine (PS). (F) Levels of CE species. (G) Levels of PS species (n = 4–6).
All data represent mean ± SEM. *p < 0.05, comparing miR-33/ with WT mice or DKO with Ldlr/ mice on the same diet.
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Mq, NOS2, or COX2, either at the gene expression or the protein
level (Figures S6C–S6E). Additionally, following treatment with
IL-4, to stimulate an alternative (M2-like) activation status, we
did not find any differences in the expression of markers of alter-
natively activated Mqs, ARG1 and FIZZ1 (Figures S6F and S6G).
Together, these findings suggest that the changes in Mq accu-
mulation and activation within the plaque may not be due to
direct regulation of Mq polarization by miR-33.
Similarly, we did not observe any differences in the induction
of apoptosis in miR-33-deficient Mqs in response to cholesterol
loading. Treatment of Mqs with Ac-LDL and an ACAT inhibitor
(Sandoz) to induce excessive free cholesterol accumulation re-
sulted in apoptosis in approximately 15% of WT cells and was
not significantly altered in Mqs lacking miR-33 (Figure S6H).
While these in vitro experiments do not properly reflect condi-
tions within the atherosclerotic plaque, they do suggest that fac-
tors other than reduced apoptosis may contribute to the lower
numbers of TUNEL-positive cells and decreased necrotic core
size found in plaques from animals transplanted with miR-33-
deficient BM. Consistent with this, we found that loss of
miR-33 increases the ability of Mqs to engulf and incorporate
fluorescently labeled apoptotic cells (Figure S6I). Interestingly,
the expression of MERTK, a kinase involved in the regulation of
efferocytosis, was found to be upregulated in miR-33/ Mqs
(Figure S6J). These findings are important, as efficient clearance
of apoptotic cells limits prolonged inflammation and may
contribute to the reduced recruitment and activation of Mqs
lacking miR-33.
Lack of miR-33 in Mqs Attenuates the Expression of
Genes Associated to Inflammatory Response In Vivo
Similar to our lipidomic analysis, we have also performed an un-
biased analysis of how gene expression levels are impacted by
loss of miR-33 in Mqs in vivo under hyperlipidemic (Ldlr/)
conditions. This approach, developed by the Glass laboratory,
allows the analysis of changes in lipid metabolism and gene
expression during foam-cell formation in vivo (Li et al., 2004).
RNA sequencing (RNA-seq) analysis has revealed a number of
pathways and specific genes that may be involved in mediating
the effects of miR-33 on Mq function and atherosclerotic plaque
formation. Furthermore, a comparison between WT and Ldlr/
mice allows us to distinguish between those genes that are
generally regulated in response to changes in lipid content and
those that are more likely to be directly regulated by miR-33
(Figure 5). Among those factors found to be significantly altered
in response to loss of miR-33 (Figure 5B), a number of important
pathways were found to be overrepresented, including those
involved in inflammation, fatty acid metabolism, cholesterol
biosynthesis, and unfolded protein response (Figures 5C and
5D). These pathways and many of the genes within them are
known to play an important role in the development of athero-
sclerotic plaques and may contribute either directly or indirectly
to the beneficial effects observed in miR-33-deficient Mqs. Addi-
tional analysis of gene expression changes between WT and
Ldlr/ mice demonstrates that many of these same pathways
are also impacted by hypercholesterolemia. Indeed, many of
the metabolic pathways that are upregulated in DKO-deficient
macrophages compared to Ldlr/ mice are downregulated in
Ldlr/ mice compared to WT (Figure 5E). This suggests that
these changes may be largely due to differences in lipid content,
while pathways related to stress response are downregulated in
both comparisons, indicating that these changes are likely regu-
lated by factors independent of lipid content. Indeed, these
changes would be predicted to result in diminished inflammatory
signaling through the NFkB (nuclear factor kB)- and TLR4-medi-
ated pathways, resulting in a reduction in Mq activation and
polarization in vivo (Figures 6A and S7). Moreover, some of the
specific changes in lipid sub-species that we have observed in
miR-33/ macrophages may also contribute to the observed
changes in inflammatory response. Among the molecules that
are known to interact with phosphatidylserine and phosphatidyl-
ethanolamine, many were found to be dysregulated by loss of
miR-33 in our RNA-seq analysis. Indeed, the observed de-
creases in these two classes of lipids could be predicted to pro-
mote many of these changes in gene expression, and the overall
changes in these genes are predicted to result in a decrease in
inflammatory response (Figure 6B). While additional work will
be needed to identify the specific miR-33 targets responsible
for mediating many of these effects, these data provide an
important resource for establishing how changes in lipid content
and miR-33 levels impact global gene expression patterns in
Mqs in vivo.
Overall, this work demonstrates that loss of miR-33 selectively
in hematopoietic cells is sufficient to reduce Mq recruitment and
lipid accumulation in atherosclerotic plaques. The beneficial ef-
fects, however, are offset by the pro-atherogenic factors that
are found to be increased in response to whole-body loss of
miR-33, including increased BW, IR, and dyslipidemia. Alterna-
tively, Mq miR-33b was not found to have a major impact on
atherosclerosis, which is likely due to the low expression of
this isoform in Mqs compared to miR-33a (Figure 7).
DISCUSSION
As a known regulator of cholesterol efflux and HDL-C meta-
bolism, miR-33 is an attractive target for the treatment of cardio-
vascular disease, and several studies have found that antago-
nism of miR-33 can reduce atherosclerotic plaque burden
(Karunakaran et al., 2015; Ouimet et al., 2015; Rayner et al.,
2011b; Rotllan et al., 2013). Another study did not find reduced
aortic lesions in anti-miR-33-treated mice (Marquart et al.,
2013). However, the hypertriglyceridemia and hepatic steatosis
observed in some long-term anti-miR-33 studies (Allen et al.,
2014; Goedeke et al., 2014) and the adverse metabolic effects
reported inmiR-33 knockout mice (Horie et al., 2013) have raised
major concerns about the development of anti-miR-33 therapeu-
tics for treatment of human patients. Much of this concern stems
from an incomplete understanding of the mechanisms by which
miR-33 impacts atherogenesis, as highlighted by the dual role of
miR-33 regulating cholesterol efflux in Mqs and HDL biogenesis
in the liver. This question is even more important, due to the poor
performance of CETP inhibitors and other HDL-C-raising thera-
pies in recent clinical trials (Rader and deGoma, 2014; Rader
and Hovingh, 2014). If the effects of miR-33 are primarily due
to its ability to raise circulating HDL-C levels, anti-miR-33 thera-
peutics may face many of the same issues found in these
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studies, while direct effects on the ability of arterial Mqs to efflux
cholesterol may provide greater therapeutic value. Together, the
findings laid forth in this article help clarify many of the questions
regarding how miR-33 regulates atherosclerotic plaque forma-
tion, which will be necessary for evaluating the possible thera-
peutic potential of miR-33 antagonists.
Similar to previous work in Apoe/ mice (Horie et al., 2012),
we observe that reconstitution of Ldlr/mice with BM deficient
in miR-33 reduces lipid accumulation in atherosclerotic plaques.
However, the effects observed in our study are considerably
more robust, with significant reductions also observed in total
plaque size, necrotic core area, and the number of apoptotic
cells. Since the primary function of ABCA1 and ABCG1 is the
efflux of cholesterol onto poorly lipidated ApoA1 and HDL parti-
cles, respectively (Tall et al., 2008), these differencesmay be due
to the low levels of HDL-C in Apoe/mice, which could limit the
impact of elevating Mq ABCA1 levels. These findings indicate
that the ability of miR-33 to promote cholesterol efflux from arte-
rial Mqs plays a more important role in its regulation of athero-
sclerosis than was suggested by previous work. Because these
effects are independent of any changes in circulating HDL-C
levels, these findings demonstrate the potential therapeutic
value of anti-miR-33 therapies for promoting the removal of lipids
from atherosclerotic plaques and, thereby, limiting plaque
development.
Interestingly, we find that loss of miR-33 in Ldlr/mice results
in a significant increase in BW, which is exacerbated by a WD
feeding. This predisposition to diet-induced obesity is also
accompanied by decreased insulin sensitivity and increased
circulating levels of VLDL-C, and LDL-C and TAGs. Together,
Figure 5. Lack of miR-33 in Macrophages Impacts Genes Involved in Stress Response and Metabolic Function In Vivo
(A) Principal-component (PC) analysis of peritoneal macrophages (Mqs) from Ldlr/ and Ldlr/miR-33/ (DKO) mice (n = 3) based on RNA-sequencing gene
expression levels, color coded according to the group of mice.
(B) Heatmaps representing gene expression (rlog-transformed values) of genes differentially expressed between Ldlr/ and DKO Mqs.
(C) Top canonical pathways involving differentially expressed molecules and related to atherosclerosis expressed as log (p value).
(D) Heatmaps of pathways relevant to atherosclerosis that are altered in DKO mice compared to Ldlr/ controls.
(E) Heatmaps of pathways relevant to atherosclerosis that are altered in Ldlr/ mice compared to WT controls.
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Figure 6. Absence of miR-33 Attenuates NFKB Activation and Innate Immune Response
(A) NFKB signaling pathway analysis using the Ingenuity Pathway Analysis (IPA) tool. Genes represented in green are downregulated in peritoneal macrophages
(Mqs) isolated from Ldlr/miR-33/ (DKO) compared to Mqs obtained from Ldlr/ mice.
(B) Network of genes known to interact with phosphatidylserine and phosphatidylethanolamine whose expression is significantly altered in miR-33-deficient
macrophages. Prediction analysis identifies genes in which inhibition (blue) or activation (red) is predicted based on changes in these lipid species. Overall
changes in this network are predicted to inhibit inflammatory response.
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these changes likely offset the beneficial effects occurring in
plaque Mqs, as there were no differences in plaque size or lipid
accumulation in Ldlr/ mice lacking miR-33. Unfortunately,
these changes also impede our ability to address the specific
impact of miR-33’s regulation of HDL biogenesis and bile acid
metabolism in the liver. While BMT from WT mice into Ldlr/
and DKO animals would allow us to determine how effects on
the liver and other tissues impact plaque formation, it would
not help with dissociating the effects on RCT from the changes
observed in BW, IR, and circulating lipids. These effects are con-
trary to what was previously reported in Apoe/ mice lacking
miR-33, where the authors did find reduced plaque size; did
not observe any difference in circulating VLDL-C, LDL-C, or
TAGs; and did not provide any data on BW or insulin sensitivity
(Horie et al., 2012). Interestingly, a later report by the same group
did show a dramatic increase in BW and IR in miR-33/ mice
when fed a high-fat (60% saturated fat) diet (Horie et al., 2013).
Further work is currently underway seeking to elucidate the spe-
cific mechanisms by which miR-33 regulates obesity and IR, as
this will be important for the progress of any anti-miR-33 thera-
peutic efforts.
While most work on miR-33 has been done using mouse
models, humans contain a second miR-33 isoform, miR-33b,
which may also play an important role in atherosclerosis. In
this work, we begin to assess the impact of miR-33 on athero-
genesis by performing BM transplants from miR-33bKI mice
into the Ldlr/ background. Addition of miR-33b to Mqs does
not appear to have any impact on plaque formation or lipid accu-
mulation. These results are likely due to the relatively low expres-
sion of miR-33b in Mqs, compared to that of miR-33a. This
finding is not specific to our miR-33bKI mice, as Mqs derived
from human peripheral blood mononuclear cells also expressed
much higher levels of miR-33a compared to miR-33b. These dif-
ferences in miRNA expression vary between cell types, suggest-
ing that the role of miR-33b in the liver, where miR-33b is most
highly expressed both in our mouse model and in human tissues
(Najafi-Shoushtari et al., 2010), and other tissues may be con-
siderably more important. Consistent with this, a previously
Figure 7. Schematic Representation of
the Role of miR-33a and miR-33b in Athero-
genesis
described miR-33b knockin model was
reported to have decreased expression
of ABCA1 and other miR-33 target genes
in primary hepatocytes (Horie et al.,
2014). Furthermore, we found that expres-
sion of miR-33b in the liver is higher than
that of miR-33a, which could be very
interesting under conditions of obesity
and IR, where the host gene of miR-33b,
SREBP-1, is known to be dysregulated.
Unfortunately, the poor survival rates
and reduced BW of homozygous miR-
33bKI mice at birth and throughout early
adulthood has precluded any meaningful
exploration into how global addition of miR-33b impacts athero-
genesis. Further work using adult induciblemodels or other tech-
niques to overcome these developmental issues will be needed
to properly address the role of miR-33b in atherosclerosis and
other metabolic diseases.
A number of different functions of miR-33 have been
described as possibly contributing to its regulation of atheroscle-
rotic plaque formation. Among these, the ability of miR-33 to
regulate Mq cholesterol efflux and RCT is the most likely to
directly impact the accumulation of lipids within arterial Mqs
(Rayner et al., 2010, 2011b). In this work, we demonstrate for
the first time that loss of miR-33 increases the capacity of Mqs
to efflux cholesterol in vivo. Additionally, we observed an addi-
tional function of miR-33 in regulating the uptake of apoptotic
cells by Mqs in vitro, which could possibly also contribute to
the changes seen in necrotic core size. Interestingly, another
group has very recently reported similar changes in efferocytosis
upon inhibition of miR-33, which were attributed to the regulation
of autophagy by miR-33 (Ouimet et al., 2017). However, neither
the specific autophagic genes reported to be targeted by
miR-33 nor most other genes related to autophagic function
were found to be significantly altered in our RNA-seq analysis.
Alternatively, MERTK protein levels were found to be reduced
in miR-33-deficient Mqs, and miRNA prediction algorithms sug-
gest that this may targeted by the passenger strand of miR-33,
miR-33*. Finally, by using unbiased techniques for assessing
global changes in lipid profiles, and mRNA expression, we
provide a comprehensive profile of the factors influenced by
miR-33 under normal and hyperlipidemic conditions, which pro-
vides further insight into the pathways and individual gene tar-
gets responsible for mediating the effects of miR-33.
Consistent with the increased capacity to efflux cholesterol
previously observed, we find a dramatic reduction in the accu-
mulation of all different species of cholesterol esters in miR-33-
deficient Mqs under hyperlipidemic conditions. Our RNA-seq
analysis in Mqs has revealed a number of genes that are differen-
tially up- and downregulated in response to loss of miR-33.
Pathway analysis further revealed that many of these genes
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are involved in pathways that have previously been shown to be
important for the development of atherosclerosis. An additional
analysis, identifying genes that are altered under hyperlipidemic
conditions, demonstrates that many of the genes whose expres-
sion was dysregulated in response to hyperlipidemic conditions
were regulated in a reverse manner in cells lacking miR-33.
These changes are likely due to the reduced lipid accumulation
observed in miR-33-deficient Mqs; however, a large proportion
of the genes dysregulated in response to loss of miR-33 were
not found to be altered in response to dyslipidemia, suggesting
that these could be either directly or indirectly regulated by
miR-33 independent of its effects on lipid content. Among the
pathways found to be significantly overrepresented in this data-
set were important pathways involved in regulation of metabolic
function. Most of the genes in these pathways were significantly
upregulated in DKO animals. These same pathways were largely
repressed in Ldlr/ mice compared to WT, suggesting that the
reduced lipid accumulation in DKO animals is likely the primary
factor responsible for the altered expression of these genes.
Alternatively, most of the genes in pathways related to inflamma-
tion and endoplasmic reticulum (ER) stress (unfolded protein
response) were downregulated both in DKO mice compared to
Ldlr/ and Ldlr/ mice compared to WT, despite opposite
changes in lipid content. Therefore, the alterations in these
stress response pathways is likely independent of the overall
changes in lipid content. While these alterations may be medi-
ated through direct targeting of factors involved in regulation of
these pathways, our in vitro assessment of Mq polarization and
ER-stress-mediated apoptosis did not reveal any differences be-
tween miR-33/ and WT Mqs.
Interestingly, we also found reduced levels of phosphatidyl-
serine and phosphatidylethanolamine in miR-33-deficient Mqs.
These changes are not as uniform or dramatic as the reductions
in cholesterol esters but may have important effects, as these
lipid subspecies are known to play important roles inMqmobility,
phagocytosis, and apoptosis (Greenberg et al., 2006; Marin˜o
and Kroemer, 2013; Shiratsuchi et al., 1998). Consistent with
this, Lai and colleagues have recently reported that the absence
of miR-33 in Mqs alters membrane microdomains, influencing
the innate immune response (Lai et al., 2016). By overlaying
our RNA-seq data with a network of genes known to interact
with these lipid sub-species, we can identify a number of genes
that are significantly dysregulated by the loss of miR-33. Further
predictive analysis demonstrates that many of these changes
are predicted based on the observed alterations in these lipids.
Moreover, the overall changes in this gene set are predicted to
result in an inhibition of inflammatory response. This analysis in-
dicates the changes in these specific lipid classes may
contribute to the overall phenotypes observed in these mice,
including effects on pathways like inflammatory response that
were largely independent of the overall changes in lipid content.
Further work looking at how loss of miR-33 impacts lipid rafts,
membrane fluidity, and the lipid composition of atherosclerotic
plaques will provide additional insight into how these alterations
may affect atherogenesis.
Overall, this work supports the promising therapeutic potential
of miR-33 inhibitors for directly promoting the efflux of choles-
terol from arterial Mqs, thereby limiting Mq lipid accumulation
and preventing further Mq recruitment and activation. However,
our findings also highlight the potential adverse effects of inhib-
iting miR-33 in other organs due to the obesity, IR, and hyperlip-
idemia observed in whole-body miR-33/ animals. These find-
ings provide much needed insight into themechanisms by which
miR-33 regulates atherosclerotic plaque formation and meta-
bolic function and suggest that targeted inhibition of miR-33
within atherosclerotic plaques may provide a more viable thera-
peutic option for limiting atherosclerotic plaque formation as
observed in our BMT experiments. Further work elucidating the
specific mechanisms by which miR-33 regulates Mq functions
such as inflammation and efferocytosis, as well as whole-body
effects on obesity and IR, will further aid in assessing the thera-
peutic potential of miR-33 inhibition.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in the
Supplemental Experimental Procedures. Briefly, RNA-seq was performed
through the Yale Center for Genome Analysis using an Illumina HiSeq 2000
platform (13 75-bp read length). Trimmed reads were aligned using TopHat2,
and transcript abundances and differences were calculated using cuffdiff.
Gene network and pathway analysis were carried out using Gene Set
Enrichment Analysis software (Broad Institute), Qlucore Omics Explorer
v.3.2 (Qlucore AB), and Ingenuity Pathway Analysis (Ingenuity Systems
QIAGEN). Data were deposited in NCBI Gene Expression Omnibus (GEO:
GSE103133). Animal studies were approved by the Institutional Animal Care
and Use Committee of Yale University School of Medicine. WT C57BL/6 and
Ldlr/ mice were purchased from The Jackson Laboratory (Bar Harbor,
ME, USA). Generation of miR-33/ mice was accomplished with the assis-
tance of Cyagen Biosciences. Establishment of the miR-33bKI mouse model
was accomplished in collaboration with Ingenious Targeting Laboratory.
Accelerated atherosclerosis was induced by feeding mice for 12 weeks with
a western diet (WD) containing 1.25% cholesterol (D12108; Research Diets,
New Brunswick, NJ, USA). BM transplant experiments, plaque characteriza-
tion, measurements of metabolic function and of circulating and cellular lipids,
and RCT were carried out using established techniques. Statistical differences
were measured using an unpaired two-sided Student’s t test or a one-way
ANOVA with Bonferroni correction for multiple comparisons. Normality
was checked using the Kolmogorov-Smirnov test. A nonparametric test
(Mann-Whitney) was used when data did not pass the normality test. A value
of p < 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at https://doi.org/
10.1016/j.celrep.2017.10.023.
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